US Stock MarketDetailed Quotes

AVTX Avalo Therapeutics

Watchlist
  • 4.7500
  • +0.1258+2.72%
Close Mar 27 16:00 ET
  • 16.8900
  • +12.1400+255.58%
Pre 05:21 ET
3.81MMarket Cap-9P/E (TTM)

About Avalo Therapeutics Company

Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Company Profile

SymbolAVTX
Company NameAvalo Therapeutics
Listing Date11/13/2015
Founded2011
CEODr. Garry A. Neil, M.D.
MarketNASDAQ
Employees20
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address540 Gaither Road,Suite 400
CityRockville
ProvinceMaryland
CountryUnited States of America
Zip Code20850
Phone1-410-522-8707

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Garry A. Neil, M.D.
  • Chairman of the Board, President and Chief Executive Officer
  • 1.33M
  • Christopher Ryan Sullivan
  • Chief Financial Officer and Principal Accounting Officer
  • 768.55K
  • Dr. Simon C. Pedder, PhD
  • Director
  • 47.10K
  • Dr. Gilla Kaplan,PhD
  • Independent Director
  • 72.56K
  • Dr. June S. Almenoff, F.A.C.P.,M.D.,PhD
  • Independent Director
  • 71.56K
  • Dr. Magnus Persson, M.D.,PhD
  • Lead Independent Director
  • 85.56K
  • Mitchell Chan
  • Independent Director
  • 72.56K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg